These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8520877)

  • 1. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.
    Latreille J; Stewart D; Laberge F; Hoskins P; Rusthoven J; McMurtrie E; Warr D; Yelle L; Walde D; Shepherd F
    Support Care Cancer; 1995 Sep; 3(5):307-12. PubMed ID: 8520877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
    Latreille J; Pater J; Johnston D; Laberge F; Stewart D; Rusthoven J; Hoskins P; Findlay B; McMurtrie E; Yelle L; Williams C; Walde D; Ernst S; Dhaliwal H; Warr D; Shepherd F; Mee D; Nishimura L; Osoba D; Zee B
    J Clin Oncol; 1998 Mar; 16(3):1174-8. PubMed ID: 9508205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
    de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
    Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
    Ann Oncol; 1995 Oct; 6(8):805-10. PubMed ID: 8589019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
    Matsui K; Fukuoka M; Takada M; Kusunoki Y; Yana T; Tamura K; Yoshida T; Iida K; Hirashima T; Tsukada H; Ushijima S; Miyawaki H; Masuda N
    Br J Cancer; 1996 Jan; 73(2):217-21. PubMed ID: 8546909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
    Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR
    Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
    Heron JF; Goedhals L; Jordaan JP; Cunningham J; Cedar E
    Ann Oncol; 1994 Sep; 5(7):579-4. PubMed ID: 7993831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy.
    Kirchner V; Aapro M; Terrey JP; Alberto P
    Eur J Cancer; 1997 Sep; 33(10):1605-10. PubMed ID: 9389922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis.
    Kleisbauer JP; García-Girón C; Antimi M; Azevedo MC; Balmes H; Massuti-Sureda B; Contu A; Luque A; Pellier P
    Anticancer Drugs; 1998 Jun; 9(5):387-92. PubMed ID: 9660534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis.
    Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Kodama T
    Jpn J Clin Oncol; 1996 Jun; 26(3):164-8. PubMed ID: 8656557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
    Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
    Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
    Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
    Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.